Rivaxo 10gm Tablet

Description

Rivaxo 10gm Tablet

Rivaxo 10gm Tablet (Rivaroxaban) is a highly selective direct Factor Xa inhibitor with oral bioavailability. Rivaxo 10gm Tablet is chemically designated as 5-Chloro-N- ({(5S)-2-oxo-3- [4-(3-oxo-4-morpholinyl) phenyl] -1,3-oxazolidin-5-yl} methyl) -2-thiophene-carboxamide.Rivaxo 10gm Tablet molecular formula is C19H18ClN3O5S. Hemorrhagic risk As with other anticoagulants, patients taking rivaroxaban are to be carefully observed for signs of bleeding. Rivaxo 10gm Tablet is recommended to be used with caution in conditions with increased risk of hemorrhage. Rivaxo 10gm Tablet administration should be discontinued if severe hemorrhage occurs. Renal impairment Rivaxo 10gm Tablet is to be used with caution in patients with creatinine clearance 15 – 29 ml/min. Use is not recommended in patients with creatinine clearance. Reduction of Risk of Stroke and Systemic Embolism in Non-valvular Atrial Fibrillation Rivaxo (Rivaroxaban) is indicated to reduce the risk of stroke.

Uses

Reduction of Risk of Stroke and Systemic Embolism in Non-valvular Atrial Fibrillation Rivaxo (Rivaroxaban) is indicated to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation. • Treatment of Deep Vein Thrombosis Rivaxo (Rivaroxaban) is indicated for the treatment of deep vein thrombosis (DVT). • Treatment of Pulmonary Embolism Rivaxo (Rivaroxaban) is indicated for the treatment of pulmonary embolism (PE).

Side effect :

Anemia (incl. respective laboratory parameters), dizziness, headache, eye hemorrhage (incl. conjunctival hemorrhage), hypotension, hematoma, epistaxis, hemoptysis, gingival bleeding, gastrointestinal tract hemorrhage (incl. rectal hemorrhage), gastrointestinal and abdominal pains, dyspepsia, nausea, constipation, diarrhea, vomiting, pruritus

When not use :

Hypersensitivity to Rivaxo 10gm Tablet or to any of the excipient of product. • Active clinically significant bleeding. • Lesion or condition, if considered to be a significant risk for major bleeding. This may include current or recent gastrointestinal ulceration, presence of malignant neoplasms at high risk of bleeding, recent brain or spinal injury, recent brain, spinal or ophthalmic surgery, recent intracranial hemorrhage, known or suspected oesophageal varices, arteriovenous malformations, vascular aneurysms or major intraspinal or intracerebral vascular abnormalities